Any therapeutic strategy aiming to block only one route of NAD+ biosynthesis should therefore be expected to fail in tumor cells in which the enzymatic apparatus of both NAD+ production routes (via NAMPT and via NAPRT) is expressed. The gene discussed is NAMPT; the disease is neoplasm.